Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
- Prisma Health Greenville Memorial Hospital — Greenville, South Carolina
- Saint Francis Cancer Center — Greenville, South Carolina
Phase 3 Recruiting Industry
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…
Sponsor: Genmab
NCT ID: NCT06191744
Sites in South Carolina: - MUSC Hollings Cancer Center /ID# 259604 — Charleston, South Carolina
- Prisma Health /ID# 259602 — Greenville, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in South Carolina: - Prisma Health - Upstate ( Site 0158) — Greenville, South Carolina
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in South Carolina: - Prisma Health Cancer Institute — Greenville, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in South Carolina: - Medical University of S. Carolina — Charleston, South Carolina
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
- Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in South Carolina: - SC Cancer Specialists at St. Joseph's/Candler Bluffton — Bluffton, South Carolina
- St. Joseph's/Candler Smith — Bluffton, South Carolina
- Summit Cancer Care at St. Josph's/Candler Bluffton — Bluffton, South Carolina
- South Carolina Cancer Specialists — Hilton Head Island, South Carolina
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
Phase 2 Recruiting Industry
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in South Carolina: - Medical University of South Carolina ( Site 0153) — Charleston, South Carolina
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-…
Sponsor: AstraZeneca
NCT ID: NCT07123454
Sites in South Carolina: - Research Site — Myrtle Beach, South Carolina
Phase 1, Phase 2 Recruiting Academic/Other
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (…
Sponsor: Medical University of South Carolina
NCT ID: NCT05702853
Sites in South Carolina: - Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04609046
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or rec…
Sponsor: ADC Therapeutics S.A.
NCT ID: NCT04970901
Sites in South Carolina: - Hollings Cancer Center — Charleston, South Carolina
EARLY Phase 1 Recruiting Industry
This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via …
Sponsor: Presage Biosciences
NCT ID: NCT04541108
Sites in South Carolina: - Sarah Cannon Research Institute — Charleston, South Carolina
Phase 1 Recruiting Industry
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occ…
Sponsor: FBD Biologics Limited
NCT ID: NCT05892718
Sites in South Carolina: - Greenville Hospital System University Medical Center (ITOR) — Greenville, South Carolina
Recruiting Network
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06002828
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Recruiting Network
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…
Sponsor: Children's Oncology Group
NCT ID: NCT01790152
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Recruiting NIH
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To ob…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT00900198
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina